Key result
Preemptive treatment with ganciclovir directed by high levels of CMV antigenemia reduced the incidence of CMV disease compared to historical controls.
Why the study?
Does preemptive treatment with ganciclovir directed by CMV antigenemia reduce the incidence of CMV disease in at-risk patients?
Cohort (n=37)
Does preemptive treatment with ganciclovir directed by CMV antigenemia reduce the incidence of CMV disease in at-risk patients?
Answers are grounded in this paper and cite their sources.
Preemptive treatment with ganciclovir guided by CMV antigenemia surveillance significantly reduces the incidence of CMV disease compared to treating only when illness occurs.
BACKGROUND: Rapid quantifiable diagnostic techniques for the diagnosis of cytomegalovirus (CMV) infection may predict patients at risk of CMV pneumonitis and allow preemptive antiviral treatment. METHODS: Using CMV antigenemia as a prospective surveillance technique for CMV infection, we compared the outcome of preemptive treatment (PT) with ganciclovir, 10 mg/kg/day for 21 days directed by "high levels" of CMV antigenemia (PT group, n= 19), with the outcome in a group of historical controls (n=18) treated with ganciclovir when CMV illness occurred. Greater than 50 antigen-positive cells per 2 x 10(5) polymorphonuclear leukocytes was considered to be high-level antigenemia. RESULTS: Nine of the 18 controls developed high-level CMV antigenemia at a median of 33 days (range: 13-65 days) and 5 of the 9 developed CMV disease. Ten of the 19 PT group had high levels of CMV antigenemia detected at a median of 47 days (range: 20-63 days) and were given ganciclovir; none developed CMV disease. There was a significantly lower incidence of CMV disease in the PT group in comparison to controls (0 of 19 vs. 5 of 18: P=0.019). CONCLUSION: We have reduced the incidence of CMV disease using preemptive treatment, and because of a 100% negative predictive value, we omitted unnecessary antiviral prophylaxis for many at-risk patients.
No takes yet. Share an insight, caveat, or question.
Egan et al. (1998) conducted a cohort in Cytomegalovirus (CMV) infection (n=37). Preemptive treatment with ganciclovir directed by high levels of CMV antigenemia vs. Historical controls treated with ganciclovir when CMV illness occurred was evaluated on Incidence of CMV disease (p=0.019). Preemptive treatment with ganciclovir directed by high levels of CMV antigenemia reduced the incidence of CMV disease compared to historical controls.
Synapse has enriched 10 related papers. Consider them for comparative context: